Imagen de Portada

A General Framework for Designing and Evaluating Active‐Controlled Trials with Non‐Inferiority Objectives

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Antonio Olivas‐Martinez, Fei Gao, Holly Janes
Formato:	Artículo Open Access
Publicado:	Wiley 2026
Materias:	Statistics in Medicine
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A General Framework for Designing and Evaluating Active-Controlled Trials with Non-Inferiority Objectives
por: Olivas-Martinez, Antonio, et al.
Publicado: (2025)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
por: Fei Gao, et al.
Publicado: (2025)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
por: Ethan Ashby, et al.
Publicado: (2025)

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority
por: Hakim‐Moulay Dehbi, et al.
Publicado: (2025)

Nothing to See Here? A Non‐Inferiority Approach to Parallel Trends
por: Alyssa Bilinski, et al.
Publicado: (2026)

A Framework for Generating Realistic Synthetic Tabular Data in a Randomized Controlled Trial Setting
por: Niki Z. Petrakos, et al.
Publicado: (2025)

Bayesian Power Prior in Platform Trials With Non‐Concurrent Control for Binary Outcomes: Development and Comparative Evaluation
por: Junichi Asano, et al.
Publicado: (2026)

On the Inclusion of Non‐Concurrent Controls in Platform Trials With an Interim Analysis
por: Pavla Krotka, et al.
Publicado: (2026)

A Comparison of Statistical Methods for Time‐To‐Event Analyses in Randomized Controlled Trials Under Non‐Proportional Hazards
por: Florian Klinglmüller, et al.
Publicado: (2025)

An Integrated and Coherent Framework for Point Estimation and Hypothesis Testing With Concurrent Controls in Platform Trials
por: Tianyu Zhan, et al.
Publicado: (2025)

Synergy Area With FDR ‐Controlled Evaluation ( SAFE ) to Robustly Assess Safety Profile in Clinical Trials
por: Tianyu Zhan, et al.
Publicado: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
por: Yichen Yan, et al.
Publicado: (2025)

The Design of Large‐Scale Plasma Donation Trials
por: Kecheng Li, et al.
Publicado: (2025)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
por: Yingjie Qiu, et al.
Publicado: (2026)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
por: Yuan Li, et al.
Publicado: (2025)

Modern Causal Inference Approaches to Improve Power for Subgroup Analysis in Randomized Controlled Trials
por: Antonio D'Alessandro, et al.
Publicado: (2026)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
por: Gi‐Ming Wang, et al.
Publicado: (2026)

Adaptive Designs in Trials With Time‐to‐Event Endpoints and Covariate Adjustment
por: Daniel Backenroth, et al.
Publicado: (2026)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
por: Yuwei Cheng, et al.
Publicado: (2026)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
por: Alessandra Serra, et al.
Publicado: (2025)

Design and Analysis of N‐Of‐1 Trials That Incorporate Sequential Monitoring
por: Shu Jiang, et al.
Publicado: (2025)

A Saddlepoint Framework for Accurate Inference in Multicenter Clinical Trials With Imbalanced Clusters
por: Haidy A. Newer
Publicado: (2026)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
por: Moka Komaki, et al.
Publicado: (2026)

A sequential, multiple assignment, randomized trial design with a tailoring function
por: Holly Hartman, et al.
Publicado: (2024)

Bayesian Response‐Adaptive Randomization for Cluster Randomized Controlled Trials
por: Yunyi Liu, et al.
Publicado: (2026)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
por: Adrien Ollier, et al.
Publicado: (2025)

Sequential Monitoring of Covariate‐Adaptive Randomized Clinical Trials With Non‐Parametric Approaches
por: Xiaotian Chen, et al.
Publicado: (2025)

Response‐Adaptive Randomization Procedure in Clinical Trials with Surrogate Endpoints
por: Jingya Gao, et al.
Publicado: (2024)

Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles
por: Kim May Lee, et al.
Publicado: (2026)

Confidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
por: David S. Robertson, et al.
Publicado: (2025)

Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome
por: Kendra Davis‐Plourde, et al.
Publicado: (2025)

Semiparametric Estimation of Relative Causal Effects in Randomized Controlled Trials With Noncompliance
por: Wenli Liu, et al.
Publicado: (2025)

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial
por: Corine Baayen, et al.
Publicado: (2025)

Group Sequential Trial Design Using Stepwise Monte Carlo for Increased Flexibility and Robustness
por: Amitay Kamber, et al.
Publicado: (2025)

Dynamic Borrowing With a Bias‐Tolerance Cap in Augmented Randomized Controlled Trials
por: Kota Sawada, et al.
Publicado: (2026)

Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials
por: Jingyan Fu, et al.
Publicado: (2025)

Estimation and Hypothesis Testing of Strain‐Specific Vaccine Efficacy With Missing Strain Types With Application to a COVID‐19 Vaccine Trial
por: Fei Heng, et al.
Publicado: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
por: Cheng‐Han Yang, et al.
Publicado: (2026)

RMST for Interval‐Censored Data in Oncology Clinical Trials
por: Xiyuan Gao, et al.
Publicado: (2025)

Dynamic Borrowing From Historical Controls via the Synthetic Prior With Covariates in Randomized Clinical Trials
por: Daniel E. Schwartz, et al.
Publicado: (2026)